Abstract
Postprocedural chest pain remains a common problem, and irrespective of electrocardiographic changes, is associated with a higher incidence of early cardiac events. A return to the catheterization laboratory is unlikely to benefit patients with postprocedural chest pain without electrocardiographic changes with documented irreversible intraprocedural complications, or those with late postprocedural pain.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Abciximab
-
Aged
-
Angioplasty, Balloon, Coronary*
-
Antibodies, Monoclonal / therapeutic use
-
Aspirin / therapeutic use
-
Chest Pain / etiology
-
Chest Pain / prevention & control*
-
Coronary Disease / therapy*
-
Drug Therapy, Combination
-
Electrocardiography
-
Female
-
Humans
-
Immunoglobulin Fab Fragments / therapeutic use
-
Male
-
Platelet Aggregation Inhibitors / therapeutic use*
-
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
-
Prognosis
-
Prospective Studies
-
Recurrence
-
Stents*
-
Ticlopidine / therapeutic use
Substances
-
Antibodies, Monoclonal
-
Immunoglobulin Fab Fragments
-
Platelet Aggregation Inhibitors
-
Platelet Glycoprotein GPIIb-IIIa Complex
-
Ticlopidine
-
Aspirin
-
Abciximab